Skip to content

Cart

Your cart is empty

Colon cancer immunotherapy: what the new Nature Medicine UNICORN trial found

Colon Cancer Immunotherapy: The New Study, in Plain English

Stefan Stefan
6 minute read

Listen to article
Audio generated by DropInBlog's Blog Voice AI™ may have slight pronunciation nuances. Learn more

Table of Contents

Colorectal cancer (colon plus rectal) is now the #1 cause of cancer death in men under 50 in the US, and #2 in women. In the late 1990s, it ranked fourth for both.[1] A 2026 update went further: in 2023, for everyone under 50, men and women combined, it was the top cancer killer.[2] That's the backdrop for the new colon cancer immunotherapy results I want to share.

So why is a coffee company talking about colon cancer? Honestly, because it's close to home. I'm 34, and most of our friends are somewhere between 30 and 50. That's right in the age group of that stat, and it's scary.

Then, doing some weekend reading, I came across a new colon cancer immunotherapy study. It feels like we're making real strides. Here's the study[3] if you want to jump in. Otherwise, here's my quick breakdown of the highlights and what I was personally pretty excited about.

What this colon cancer immunotherapy study did

Researchers gave 56 people with colon cancer a short course of immunotherapy before their planned surgery. Immunotherapy is medicine that helps your own immune system go after cancer. The main drug was botensilimab, given alone or with a second drug, balstilimab. After surgery, they looked at the removed tissue under a microscope to see how much cancer was left.[3]

The trial is called UNICORN, and it was published in Nature Medicine this month. Great name, by the way.

4 things I was excited about

  1. 13 out of 14 people in one group had no cancer left in the tissue removed at surgery. In the best group, the lab found no living cancer cells in the tissue for 13 of 14 people. That's 93%. Kind of like showing up to a mess and finding the cleanup crew already finished.
  2. It worked on the stubborn kind too. For this study, colon tumors were split into two groups. One has a broken DNA "spell-check," so it's full of typos, which makes it easier for the immune system to spot once the brakes come off. The other type blends in and usually ignores immunotherapy. In that stubborn group, 4 of the 14 people who got both drugs had no cancer left in the removed tissue. That's 29%.
  3. Two drugs looked way better than one. Think of this kind of immunotherapy as taking the brakes off your immune system. Each of these two drugs releases a different brake. One drug alone helped some people, but in the stubborn group it got no big responses at all. Together, the results jumped.
  4. It all happened before surgery, and nobody missed surgery. Everyone got a short round of the drugs, then went ahead with their planned operation. Every single patient made it to surgery, and all but one stayed on schedule. Kind of like a warm-up before the main event.

All four of those come straight from the paper.[3] I'm into that. It's not every day you read a cancer study and feel hopeful.

The catch, quickly

This is a small, early study. 56 people, split into 4 groups of 14, with no comparison group, and patients weren't randomly assigned. Almost all of them were white, so we don't know yet how well this carries over to everyone else. So it's a promising signal, not proof. Colon cancer immunotherapy before surgery is still a research question, not a standard treatment.

No cancer found at surgery is a great sign, but it isn't the same as being in the clear for good. The researchers are still following these patients, and they've added a bigger group to set up a larger trial. Side effects were real too. About 4 in 10 people overall had immune-related side effects, and with the two-drug combo it was about half, mostly flu-like symptoms and diarrhea. One person had a serious thyroid problem that pushed their surgery back.[3]

So this isn't something you can ask your doctor for tomorrow. It's progress worth knowing about.

What you can do about colorectal cancer this week

Studies like this are for doctors and research teams. Screening is for the rest of us. The American Cancer Society says average-risk adults should start at 45, and you have options, from a colonoscopy to an at-home stool test. If your colonoscopy is normal and you're average risk, the next one is usually 10 years later.[4] If it runs in your family, ask your doctor about starting earlier.

And if you notice blood in your stool, a change in bathroom habits that lasts more than a few days, or weight loss you can't explain, don't wait for 45. Call your doctor.[5] If you're 45+ and putting it off, this is your nudge. If you're my age, send this to the friend who is.

Why we share stuff like this

Longevity isn't just about selling more coffee. It's about paying attention to your health, and that includes the news. When a colon cancer immunotherapy result like this comes up, we want to share it from our perspective, in plain English, in case it's helpful to you or someone you love.

To be clear, coffee has nothing to do with this study. Switching gears to the everyday stuff: for healthy aging, the boring basics still matter most. Sleep, move, eat mostly real food. Coffee is the one habit most of us never skip, which is why we make Longevity Coffee+ (BLOG12 takes 12% off if you want to try it).

-stefan

This is our take, not medical advice.

For more notes like this, join the email list.

You always forget your supplements. You never forget your coffee.

Sources

  1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: A Cancer Journal for Clinicians. 2024. doi:10.3322/caac.21820.
  2. Siegel RL, Wagle NS, Jemal A. Leading Cancer Deaths in People Younger Than 50 Years. JAMA. 2026;335(7):632-634. doi:10.1001/jama.2025.25467.
  3. Ghelardi F, et al. Neoadjuvant botensilimab with or without balstilimab in pMMR and dMMR colon cancer: the phase 2 UNICORN trial. Nature Medicine. Published 2 November 2026. Read the UNICORN trial in Nature Medicine. ClinicalTrials.gov: NCT05845450.
  4. American Cancer Society. Colorectal Cancer Guideline: How Often to Have Screening Tests.
  5. American Cancer Society. Colorectal Cancer Signs and Symptoms.

FAQs

What did the new colon cancer immunotherapy study find?

In the UNICORN trial, 13 of 14 people in the best group had no living cancer cells left in the tissue removed at surgery after a short course of two immunotherapy drugs. In the tumor type that usually ignores immunotherapy, 4 of the 14 who got both drugs did. It's a small, early study.[3]

Does "no cancer left in the removed tissue" mean they're in the clear for good?

Not on its own. It's a great early sign, but it isn't the same as long-term results. The researchers are still following these patients.[3]

Can I get this immunotherapy now?

Not as a standard option. It's an early trial, and the researchers have added a bigger group to set up a larger study. If this touches your life, ask your doctor about clinical trials.[3]

Is colorectal cancer really the top cancer killer for people under 50?

Yes, in the US. The American Cancer Society reports it's #1 for cancer deaths in men under 50 and #2 in women, up from fourth in the late 1990s.[1] A 2026 JAMA report found it's now #1 for men and women under 50 combined.[2]

When should I start colorectal cancer screening?

The American Cancer Society says 45 for average-risk adults, earlier if you're at higher risk. A colonoscopy and at-home stool tests are both options, and any abnormal stool test needs a follow-up colonoscopy.[4]

« Back to Blog